Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Geralyn Messerlian is active.

Publication


Featured researches published by Geralyn Messerlian.


Obstetrics & Gynecology | 2004

Inverse correlation between maternal weight and second trimester circulating cell-free fetal DNA levels

Tuangsit Wataganara; Inga Peter; Geralyn Messerlian; Lynn Borgatta; Diana W. Bianchi

OBJECTIVE: Clinical applications of the analysis of cell-free fetal DNA in maternal plasma and serum are expanding. However, use of fetal DNA during prenatal screening requires knowledge of variables that might affect its levels in the maternal circulation. We conducted this study to estimate the effect of selected demographic factors on fetal DNA levels in the first and second trimesters of pregnancy. METHODS: We developed a database that included fetal DNA levels and clinical information, such as maternal age, ethnicity, weight, and smoking history. We measured fetal DNA levels in maternal plasma and serum using real-time quantitative polymerase chain reaction amplification of a Y chromosome specific sequence. The fetal DNA data from fresh first trimester plasma and previously frozen second trimester serum samples were analyzed separately. Fetal DNA levels were adjusted according to gestational age and storage time and then analyzed in association with the demographic factors. RESULTS: In the first trimester group, no significant association between maternal age, weight, ethnic background, or smoking and plasma fetal DNA levels was observed. In the second trimester group, a significant inverse correlation between maternal weight and serum fetal DNA level was demonstrated (r = −0.26, P = .007). This was especially prominent when the mothers weighed more than 170 lb (P = .001). Maternal age, ethnicity, and smoking were not significantly associated with the second trimester serum fetal DNA levels. CONCLUSION: Fetal DNA levels are affected by maternal weight in the second trimester. A correction for this effect may be needed in larger-scale studies or for future clinical applications that measure cell-free fetal nucleic acids in maternal circulation. LEVEL OF EVIDENCE: II-3


American Journal of Reproductive Immunology | 2015

Impact of CD4+ Lymphocytes and HIV Infection on Anti-Müllerian Hormone Levels in a Large Cohort of HIV-infected and HIV-uninfected Women

Rebecca Scherzer; Peter Bacchetti; Geralyn Messerlian; Johanna L. Goderre; Pauline M. Maki; David B. Seifer; Kathryn Anastos; Roksana Karim; Ruth M. Greenblatt

Effects of HIV infection on ovarian function and aging are unclear.


Prenatal Diagnosis | 2015

Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures

Glenn E. Palomaki; Elizabeth Eklund; Louis M. Neveux; Geralyn Messerlian

Examine primary Down syndrome screening using combinations of first trimester serum markers, with and without sequencing of cell free DNA as a secondary reflexive test.


Gynecologic Oncology | 2008

THE USE OF MULTIPLE NOVEL TUMOR BIOMARKERS FOR THE DETECTION OF OVARIAN CARCINOMA IN PATIENTS WITH A PELVIC MASS

Richard G. Moore; Amy K. Brown; M. Craig Miller; Steven J. Skates; W. Jeffrey Allard; Thorsten Verch; Margaret M. Steinhoff; Geralyn Messerlian; Paul DiSilvestro; C.O. Granai; Robert C. Bast


American Journal of Obstetrics and Gynecology | 2002

Down syndrome and cell-free fetal DNA in archived maternal serum.

Thomas Lee; Erik S. LeShane; Geralyn Messerlian; Jacob Canick; Antonio Farina; Walter Heber; Diana W. Bianchi


Human Genetics | 2003

Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18.

Tuangsit Wataganara; Erik S. LeShane; Antonio Farina; Geralyn Messerlian; Thomas H. Lee; Jacob A. Canick; Diana W. Bianchi


American Journal of Obstetrics and Gynecology | 2005

Subclinical hypothyroidism and pregnancy outcomes

Jane Cleary-Goldman; Fergal D. Malone; Geralyn Messerlian; Lisa M. Sullivan; Jacob A. Canick; T. Flint Porter; David A. Luthy; Susan Gross; Mary E. D'Alton


Gynecologic Oncology | 2018

The utility of additional ovarian cancer biomarkers to the dual marker combination of HE4 and CA-125 for the detection of cancer

A.M. Blackman; M.C. Miller; E. Eklund; R.M. Strongin; Geralyn Messerlian; Richard G. Moore


Gynecologic Oncology | 2017

The differential analysis of serum HE4 levels in epithelial ovarian cancer and other malignant tumors

J.E. Mitchell; M.C. Miller; Rakesh K. Singh; Geralyn Messerlian; Richard G. Moore


European Respiratory Journal | 2013

Progesterone may play a protective role in the pathogenesis of SDB in pregnancy

Hasina Meridia; Geralyn Messerlian; Patrizia Curran; Kristen Butterfield; Ghada Bourjeily

Collaboration


Dive into the Geralyn Messerlian's collaboration.

Top Co-Authors

Avatar

Diana W. Bianchi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Inga Peter

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge